Intellipharmaceutics International Inc.

    Intellipharmaceutics International Inc.

    OOTC:IPCIF
    - -
    USD
    - -
    - -
    Intellipharmaceutics International Inc.
    OTC:IPCIF
    (OTC Markets)

    Recent

    price

    - -

    P/E

    ratio

    - -

    div

    yld

    - -

    ROIC.AI

    2007
    2008
    2009
    2010
    2011
    2012
    2013
    2014
    2015
    2016
    2017
    2018
    2019
    2020
    2021
    2022
    TTM
    USD
    - -
    - -
    - -
    1.34
    0.33
    0.06
    0.78
    3.8
    1.72
    0.84
    1.77
    0.36
    0.16
    0.06
    - -
    - -
    0.03
    Revenue per Share
    -14.59
    -5.78
    - -
    -5.28
    -3.25
    -3.56
    -5.84
    -1.67
    -3.13
    -3.8
    -2.86
    -2.89
    -0.37
    -0.14
    -0.17
    -0.09
    -0.1
    Basic EPS, GAAP
    -13.11
    -5.46
    - -
    -5.8
    -4.83
    -5.04
    -3.58
    -1.08
    -1.77
    -2.54
    -2.56
    -2.65
    -0.31
    - -
    -0.08
    -0.04
    - -
    Free Cash Flow per Basic Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Dividend per Share
    -193.53
    -143.04
    - -
    -17.48
    -15.97
    -17.43
    -21.14
    -19.71
    -22.25
    -23.6
    -11.8
    -8.67
    -2.23
    -2.16
    -1.8
    -1.69
    -1.76
    Book Value per Share
    11.84
    2.91
    - -
    0.09
    -2.06
    -1.02
    -3.03
    2.13
    -0.06
    0.42
    0.12
    0.86
    -0.17
    -0.27
    -0.28
    -0.32
    -0.39
    Tangible Book Value per Share
    2
    2
    - -
    1
    1
    2
    2
    2
    2
    3
    3
    5
    22
    24
    29
    33
    33
    Basic Weighted Avg Shares
    - -
    - -
    - -
    1
    1
    - -
    2
    9
    4
    2
    6
    2
    3
    1
    - -
    - -
    1
    Sales/Revenue/Turnover
    - -
    - -
    - -
    -412.22
    -1,549.72
    -9,347.14
    -446.4
    -40.28
    -173.76
    -438.41
    -150.17
    -778.07
    -225.11
    -333.8
    - -
    -4,336.82
    -279.57
    Operating Margin (%)
    1
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    1
    1
    1
    - -
    - -
    - -
    - -
    Depreciation Expense
    -29
    -13
    - -
    -6
    -5
    -6
    -11
    -4
    -7
    -10
    -9
    -14
    -8
    -3
    -5
    -3
    -3
    Net Income, GAAP
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Effective Tax Rate (%)
    - -
    - -
    - -
    -394.76
    -972.53
    -5,730.51
    -752.55
    -43.97
    -181.65
    -451.43
    -160.91
    -802.66
    -232.28
    -241.95
    - -
    -4,400.55
    -350.72
    Profit Margin (%)
    23
    7
    5
    -1
    3
    -1
    -2
    3
    -2
    2
    -1
    3
    -6
    -8
    -9
    -12
    -14
    Working Capital
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    LT Debt
    23
    7
    5
    - -
    -3
    -2
    -6
    5
    - -
    1
    - -
    4
    -4
    -6
    -8
    -11
    -13
    Total Equity
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Common Equity (%)

    Capital Structure

    USD

    •

    in mil. unless spec.
    Feb'23
    May'23
    Aug'23
    ST Debt
    2
    2
    2
    LT Borrowings
    - -
    - -
    - -
    LT Finance Leases
    - -
    - -
    - -
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    33
    33
    33
    Market Capitalization
    2
    2
    3

    Working Capital

    USD

    •

    in mil. unless spec.
    Feb'23
    May'23
    Aug'23
    Total Current Assets
    1
    1
    1
    Cash, Cash Equivalents & STI
    - -
    - -
    - -
    Accounts Receivable, Net
    - -
    - -
    - -
    Inventories
    - -
    - -
    - -
    Total Current Liabilities
    13
    13
    14
    Payables & Accruals
    10
    10
    11
    ST Debt
    2
    2
    2
    Deferred Revenue
    - -
    - -
    - -

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    -12.29%
    180.32%
    29.69%
    Free Cash Flow
    -244.35%
    -501.47%
    -43.6%
    Net Income, GAAP
    10.13%
    -7.22%
    -43.78%
    Sales/Revenue/Turnover
    - -
    - -
    - -
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2021
    - -
    - -
    - -
    - -
    - -
    2022
    - -
    - -
    - -
    - -
    - -
    2023
    - -
    - -
    - -
    - -
    - -

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2021
    -0.04
    -0.04
    -0.04
    - -
    -0.17
    2022
    -0.03
    -0.03
    -0.01
    - -
    -0.09
    2023
    -0.01
    - -
    -0.06
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2021
    - -
    - -
    - -
    - -
    - -
    2022
    - -
    - -
    - -
    - -
    - -
    2023
    - -
    - -
    - -
    - -
    - -
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • defenseworld.net

      Analyzing Nuvo Pharmaceuticals (OTCMKTS:MRVFF) and Intellipharmaceutics International (OTCMKTS:IPCIF)

    • defenseworld.net

      Reviewing Intellipharmaceutics International (OTCMKTS:IPCIF) & Neoleukin Therapeutics (NASDAQ:NLTX)

    • accesswire.com

      Intellipharmaceutics Announces Downgrade to OTC Expert Market

    • accesswire.com

      Intellipharmaceutics International Inc. Announces Transfer of Listing to NEX and New Stock Option Plan

    • accesswire.com

      Intellipharmaceutics Announces Cease Trade Order

    • accesswire.com

      Intellipharmaceutics Announces Its Expected Delay in Filing Annual Audited Financial Statements and Annual Information Form

    • accesswire.com

      Intellipharmaceutics International Inc. Announces Stock Option Grant

    • accesswire.com

      Intellipharmaceutics International Inc. Receives Conditional Approval to List on the TSX Venture Exchange

    • accesswire.com

      Intellipharmaceutics Announces Third Quarter 2023 Results

    • accesswire.com

      Intellipharmaceutics Reports Director Election Results

    • accesswire.com

      Intellipharmaceutics Announces Closing of CAD$3.85 Million Non-Brokered Private Placement

    • accesswire.com

      Intellipharmaceutics Announces First Quarter 2021 Results